**Supplementary Table 4. Characteristics of four patients who developed AIH after inactivated vaccination**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient no.** | **characteristic** | **Vaccine** | **Diagnosis** | **Days from vaccine to new onset**  | **Symptoms at presentation** | **AST/ALT/GGT/ALP at presentation (U/I)** | **Autoantibodies** | **Prevaccine history of immune- mediated disease + tests** | **Therapy** | **prognosis of disease** |
| 4004 | 38-year-old female | Corona-Vac | AIH | 16 days(after first dose) | Hepatalgia | 28/77/243/94 | −ANA (1:100) | No | Ursofalk | hospitalization treatment |
| 4012 | 52-year-oldmale | BBIBP-CorV | AIH + PBC | 3 months (after second dose) | Jaundice | 148/193/1444/945 | −ANA (1:100)−AMA−M2(1109.4 RU/mL) | Recurrent abnormal liver function without obvious etiology | Ursofalk;hydroxychloroquine | hospitalization treatment |
| 4018 | 53-year-old female | BBIBP-CorV | AIH | 1 month (after second dose) | Jaundice | 205/244/337/464 | −ANA (1:100) | No | Ursofalk | hospitalization treatment |
| 4077 | 47-year-old female | Corona-Vac | AIH | 3 months (after second dose) | No | 173/239/23/NA | −ANA (1:100)−ASMA (1:100) | No | Ursofalk;meprednisone | outpatient treatment |

AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibody; AMA-M2, antimitochondrial antibody-M2; ANA, antinuclear antibody; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.